SARCOMA CANCER IRELAND

Contact Information SARCOMA CANCER IRELAND ST LAWRENCE LODGE. 18 STATION ROAD, SUTTON, DUBLIN 18, Ireland   Email: support@sarcoma.ie Phone/Helpline: +353 87 6753734 Web: www.sarcoma.ie   Facebook: https://www.facebook.com/sarcomaireland Twitter: https://twitter.com/sarcomaireland Linkedin: https://ie.linkedin.com/company/sarcoma-ireland Instagram: https://www.instagram.com/sarcomacancerireland/?igshid=YmMyMTA2M2Y%3D   Contact Person Ms. Rebecca Guilfoyle   Organisation Profile SARCOMA CANCER IRELAND is a non-profit, was set up in 2021 and is…

Read More

India: Sachin Sarcoma Society

  Contact Information SACHIN SARCOMA SOCIETY House No. 567, Mukhmelpur, North West Delhi Delhi 110036, India Email: support@sachinsarcomasociety.org Phone/Helpline +91 96672 48800 Web: www.sachinsarcomasociety.org Facebook: www.facebook.com/sachinsarcomasociety Twitter: https://twitter.com/SachinSarcoma?s=20&t=JPsJ0iY9QE_8WCTGhHcovQ Youtube: https://www.youtube.com/channel/UC3WwPYZZgWI6dB68iYlxuyA/featured Linkedin: https://in.linkedin.com/in/rashi-kapoor-11974b92 Instagram: https://www.instagram.com/sachinsarcomasociety/?hl=en   Contact Person Ms. Rashi Kapoor Organisation Profile Sachin Sarcoma Society is a patient support group that was formed in 2018…

Read More

Register now: SPAGN Annual Conference & New Horizons GIST 2023

Register now! 2023 SPAGN Annual Conference May 11-13, 2023 in Dublin/Ireland NEW HORIZONS GIST May 13-15, 2023 in Dublin/Ireland For the first time ever, the SPAGN Annual Conference and the New Horizons GIST Meeting will be held hand in hand. Since 2010, SPAEN/SPAGN has organized the SPAEN/SPAGN Annual Conferences to bring sarcoma, GIST and desmoid…

Read More

Mantra-2: Milademetan in advanced/metastatic solid tumors incl. sarcomas

  Agents: Milademetan Phase II Status Recruiting Sponsor Rain Oncology   For further information please also consult ClinicalTrials.gov.   This is a phase II basket study that evaluates the safety and efficacy of milademetan in patients with advanced or metastatic solid tumors with specific mutations (wild-type (WT) TP53 or MDM2) after standard-of-care therapy.   WHO…

Read More

TNG908 in MTAP-deleted Solid Tumors including MPNST

Safety and tolerability of TNG908 in MTAP-deleted solid tumors including malignant peripheral nerve sheath tumor (MPNST) Agents: TNG908 Phase I/II Status Recruiting Sponsor Tango Therapeutics   Further information on Clinicaltrials.gov.   Phase I/II study in solid tumor patients with a specific genetic mutation, a MTAP deletion, including malignant peripheral nerve sheath tumors (MPNST) WHO is…

Read More

What are your priorities in bone sarcoma research?

Research Priorities in Bone Sarcomas Bone sarcomas are a diverse and hard to treat group of rare cancers. People with bone sarcomas (or primary bone cancer) have high unmet medical needs, and face a range of challenges including delays to diagnosis, disparities in access to treatments and a relative lack of clinical trial and research opportunities.…

Read More

Looking back on 2022 and ahead to 2023

How was 2022 for your organization? What accomplishments are you proud of?

We at SPAGN are looking back at what we have done in the past year to impact the treatment and survival of sarcoma patients. We also want to look ahead to our plans for the near future.

Read More